CEO Lynx Biosciences, Inc., California, United States
The development of novel technologies for the multi-omic analysis of cancer cells in the context of their microenvironment is an essential step in our quest to unravel cancer biology and develop more efficacious therapeutic regimens. The most advanced analytical technologies currently allow for high content phenotyping and additional -omics analyses for split patient samples. However, approaches allowing for truly integrated multi-omic analyses of primary cocultures remain very limited. Current clinical strategies implement single-omic perspectives as “single point-of-view” components in diagnostic and testing panels; this prevents the comprehensive profiling of patients’ biopsies and has shown a poor correlation with response rates and limited interpretability. The combined multi-omic analysis of the same cells in a single platform is particularly challenging for suspension cells due to their non-adherent nature and susceptibility to shear forces. We developed a fully integrated, multi-omic ex vivo profiling platform for IO applications as a model. The resulting high-throughput and high-content technology combines multiplexed fluorescence microscopy imaging, soluble factor, and gene expression analysis, enabling the simultaneous, comprehensive characterization of primary target and effector cells within a clinically relevant microenvironment. This truly multi-omic platform yields an unprecedented depth of complementary information for patients using their biopsy to understand underlying disease biology and evolution, without the requirement of splitting samples for parallel analyses.
